Merit Medical Systems (NASDAQ:MMSI) Issues FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 4.010-4.150 for the period, compared to the consensus earnings per share estimate of 3.730. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.6 billion.

Analysts Set New Price Targets

MMSI has been the topic of a number of research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merit Medical Systems in a research note on Monday, December 29th. Needham & Company LLC decreased their price target on Merit Medical Systems from $108.00 to $101.00 and set a “buy” rating on the stock in a report on Wednesday. Canaccord Genuity Group raised their price objective on shares of Merit Medical Systems from $93.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $108.00 target price on shares of Merit Medical Systems in a research note on Tuesday, December 16th. Finally, Zacks Research cut Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and an average target price of $103.33.

Merit Medical Systems Trading Up 1.1%

Merit Medical Systems stock traded up $0.84 during midday trading on Thursday, reaching $80.07. 82,948 shares of the stock traded hands, compared to its average volume of 727,608. Merit Medical Systems has a 12-month low of $77.62 and a 12-month high of $107.27. The company has a 50-day simple moving average of $83.92 and a two-hundred day simple moving average of $84.94. The firm has a market cap of $4.75 billion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 2.24 and a beta of 0.61. The company has a current ratio of 4.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.48.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.08. The business had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 14.06% and a net margin of 8.48%.The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Research analysts expect that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Merit reported better‑than‑expected Q4 results: $1.04 EPS vs. $0.96 consensus, revenue $393.9M (up 10.9% y/y), and expanding margins — results investors view as evidence of underlying growth and operational leverage. Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand
• Positive Sentiment: Management set FY‑2026 EPS guidance of $4.01–$4.15, above the Street consensus (~$3.73), signaling revenue growth and margin expectations that support a higher valuation if execution continues. Earnings release & guidance
• Positive Sentiment: Barrington Research raised its price target to $109 and kept an “outperform” rating, reflecting bullish view on upside from recent results and guidance. Barrington Research raises PT
• Neutral Sentiment: Analyst commentary (Needham) kept a Buy rating based on the Q4 beat and stronger 2026 outlook, even though the firm trimmed its price target to $101 — a sign of confidence in fundamentals despite a more conservative valuation. Needham note on PT cut
• Neutral Sentiment: Company slide deck and earnings call materials are available for investors to review details on geographic mix, Cardiovascular strength, and the planned divestiture of DualCap as part of portfolio optimization. Slide deck / press release
• Negative Sentiment: Wells Fargo downgraded MMSI from Overweight to Equal Weight and cut its target to $78, flagging valuation/headwinds that could pressure near‑term sentiment. Wells Fargo downgrade

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in Merit Medical Systems by 377.7% during the 3rd quarter. Wellington Management Group LLP now owns 1,240,509 shares of the medical instruments supplier’s stock worth $103,248,000 after acquiring an additional 980,823 shares during the period. Iron Triangle Partners LP acquired a new stake in shares of Merit Medical Systems during the fourth quarter worth $33,992,000. Champlain Investment Partners LLC purchased a new position in Merit Medical Systems in the 4th quarter valued at $32,359,000. Nomura Holdings Inc. grew its position in Merit Medical Systems by 195.1% in the 3rd quarter. Nomura Holdings Inc. now owns 407,991 shares of the medical instruments supplier’s stock valued at $33,957,000 after buying an additional 269,752 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after purchasing an additional 234,682 shares in the last quarter. 99.66% of the stock is owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.